全文获取类型
收费全文 | 1018篇 |
免费 | 87篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 27篇 |
妇产科学 | 18篇 |
基础医学 | 184篇 |
口腔科学 | 26篇 |
临床医学 | 51篇 |
内科学 | 166篇 |
皮肤病学 | 19篇 |
神经病学 | 36篇 |
特种医学 | 23篇 |
外国民族医学 | 1篇 |
外科学 | 170篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 75篇 |
眼科学 | 9篇 |
药学 | 95篇 |
中国医学 | 13篇 |
肿瘤学 | 161篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 26篇 |
2021年 | 45篇 |
2020年 | 25篇 |
2019年 | 35篇 |
2018年 | 54篇 |
2017年 | 35篇 |
2016年 | 47篇 |
2015年 | 32篇 |
2014年 | 51篇 |
2013年 | 67篇 |
2012年 | 74篇 |
2011年 | 73篇 |
2010年 | 43篇 |
2009年 | 44篇 |
2008年 | 63篇 |
2007年 | 59篇 |
2006年 | 62篇 |
2005年 | 47篇 |
2004年 | 46篇 |
2003年 | 33篇 |
2002年 | 34篇 |
2001年 | 13篇 |
2000年 | 14篇 |
1999年 | 8篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 6篇 |
1995年 | 8篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1978年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有1107条查询结果,搜索用时 265 毫秒
81.
83.
Lynn Joanne; Cobbs Elizabeth; Orenstein Jan; Madigan Coleen M.; Atkins Carl D.; Goldhahn Jr Richard T.; Sangani Bakul; Kalyanaraman Venkataraman; Bhargava Mukesh; Dwek Joe H.; Bewtra Chhanda; Gistrak Michael; Saqi Anjali; Hoda Syed A.; Machin Tomas; Wecht Cyril H.; Burton Elizabeth C. 《JAMA》1999,281(23):2181-2181; author reply 2185
84.
Clemens Aigner Mir Ali Reza Hoda Gyoergy Lang Shahrokh Taghavi Gabriel Marta Walter Klepetko 《European journal of cardio-thoracic surgery》2008,34(1):204-207
BACKGROUND: Malignant pleural mesothelioma is a mainly asbestos-related neoplasm that occurs with increasing frequency and is associated with a poor prognosis. Extrapleural pneumonectomy which was initially performed as a stand-alone treatment in patients with resectable disease is now currently almost uniformly applied as part of a multi-modal approach. Its value and advantage over other therapeutic strategies remain points of discussion. We therefore analysed our experience with extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. METHODS: We retrospectively reviewed our institutional experience with all consecutive patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma from 1994 to 2005. Patients were analysed with regard to hospital mortality and morbidity and long-term outcome. RESULTS: Forty-nine patients (10 female/39 male, mean age 58+12 years) underwent extrapleural pneumonectomy during the observation period. Median ICU stay was 1 day, median postoperative length of hospital stay was 13 days. After a mean follow-up of 2573 days, median survival was 376 days (mean 672+121 days, range 9-3384). One-year survival was 53%, 3-year survival 27% and 5-year survival 19%. CONCLUSION: Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma. The long-term results of this limited series compare favourably to non-surgical treatment regimens. Larger randomised prospective multi-centre trials are warranted to establish clear guidelines. 相似文献
85.
Comparison of turbo‐PUVA and conventional American‐style PUVA in the treatment of psoriatic patients
Hoda Ahmed M. Moneib Samar Aballah Mohamed Salem Rehab Mohamed Mounir Younis 《Photodermatology, photoimmunology & photomedicine》2010,26(4):205-210
Background: Ultraviolet (UV)A protective properties of dihydroxyacetone (DHA) have been used as a topical UV‐resisting barrier to optimize psoralens and UVA (turbo‐PUVA). Starting doses and increments were based on the DHA diffuse reflectance spectroscopy‐derived protection factor. Objective: To evaluate the efficacy of turbo‐PUVA in psoriatic patients using a simpler method for determining starting doses and increments, in comparison to the conventional American‐style PUVA photochemotherapy. Methods: Thirty psoriasis patients (15 on American‐style PUVA and 15 on turbo‐PUVA) were evaluated, each receiving PUVA twice weekly. Starting UVA dose was determined according to skin phototype for the American‐style PUVA group and according to the patient's skin phototype × DHA SPF 3 in turbo‐PUVA group. UVA increments used were 0.5–1.5 J/cm2 per treatment in American‐style PUVA and 25% of the previous dose in turbo‐PUVA. Results: Turbo‐PUVA group showed a significantly lower mean cumulative dose, a significantly higher psoriasis area and severity index score reduction, lesser mean number of treatment sessions, and less duration of treatment till remission (188.44±106.2 J/cm2, 92.164±1.975%, 11.2±3.52 session, and 1.4±0.44 months, respectively) than conventional American‐style PUVA group (255.13±18.304 J/cm2, 74.725±10.976%, 30±0.00 sessions, and 3.75±0.00 months, respectively). Conclusion: Turbo‐PUVA is more effective and time convenient for the treatment of psoriasis with less cumulative dose than the conventional American‐style PUVA. 相似文献
86.
87.
Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. 总被引:2,自引:0,他引:2
Jason A Zell S-H Ignatius Ou Argyrios Ziogas Hoda Anton-Culver 《Journal of clinical oncology》2005,23(33):8396-8405
PURPOSE: Classification changes for bronchioloalveolar carcinoma (BAC) by the WHO in May 1999 narrowed its definition. This study was undertaken in an attempt to characterize the impact of these changes on the epidemiology of BAC. PATIENTS AND METHODS: This retrospective study involves data analysis from the population-based Cancer Surveillance Programs of three Southern California counties from 1995 to 2003. BAC cases diagnosed after May 1999 are compared with BAC cases before that time by clinicopathologic variables including survival. RESULTS: Incident cases (11,969) of non-small-cell lung cancer (NSCLC) were analyzed, including 626 cases of BAC (5.2%). Median overall survival (OS) for BAC patients diagnosed after May 1999 (> 53 months) was significantly improved over median OS for BAC patients before May 1999 (32 months; P = .012). This survival benefit remained after adjustment for sex, smoking status, and stage at presentation (hazard ratio for time of diagnosis before May 1999 compared with a diagnosis after May 1999 = 1.43; P = .015). Median OS for non-BAC NSCLC patients diagnosed before May 1999 (9 months) did not differ from the median OS of such patients afterwards (10 months; P = .09). CONCLUSION: This epidemiologic study is the first to demonstrate a survival advantage for BAC patients diagnosed after May 1999 compared with BAC patients diagnosed before this time-a finding that persists after adjustment for sex, smoking status, and stage at presentation. We believe that this observed survival benefit likely reflects changes in the revised 1999 WHO classification. 相似文献
88.
89.
Amro Mohamed Sedky El-Ghammaz Hoda Ahmed Gadallah Gihan Kamal Mohammed Magdy Maher Mohamad Ayed Mohamad 《Clinical and experimental medicine》2018,18(4):505-512
Programmed death ligand-1 (PD-L1) plays an important role in the immune evasion of cancer cells and, in turn, can influence the outcome of many malignancies. The serum soluble PD-L1 (sPD-L1) levels were measured in diffuse large B cell lymphoma (DLBCL) patients at diagnosis and at end of treatment. Their impact on end of treatment metabolic response was analyzed. Serum sPD-L1 level was significantly elevated in DLBCL patients at diagnosis than in controls (P?<?0.001). Also, serum sPD-L1 level at diagnosis was significantly higher than that at end of treatment (P?<?0.001). Patients who achieved partial response (PR) had significantly higher serum sPD-L1 level at end of treatment than controls (P?<?0.001). In contrast, all patients especially those who achieved complete response (CR) had insignificantly different serum sPD-L1 level at end of treatment than controls (P?=?0.354 and P?=?0.090, respectively). There was a significant difference between serum sPD-L1 level at diagnosis and that at end of treatment in patients who achieved PR and CR (P?=?0.023 and P?<?0.001, respectively). On univariate analysis, presence of comorbidities, Ann Arbor stage IV, high serum sPD-L1 level at diagnosis and high serum sPD-L1 level at end of treatment were significantly associated with achievement of PR (P?=?0.018 and P?=?0.043, P?=?0.045 and P?<?0.001, respectively). On multivariate analysis, serum sPD-L1 levels at diagnosis and at end of treatment were still influencing metabolic response significantly (P?=?0.014 and P?=?0.007, respectively). Serum sPD-L1 is a predictor for metabolic response to immunochemotherapy in DLBCL patients. 相似文献
90.